Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets

Contributed by: Business Wire

Tags

Professional Services

Health

Other Health

Finance

Clinical Trials

Pharmaceutical

Biotechnology

Alfasigma S.p.A

More Like This

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Almirall HQ in Barcelona (Photo: Business Wire)

Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline

Almirall’s 2025 Results

Almirall’s 2025 9M Results

Almirall HQ in Barcelona (Photo: Business Wire)

Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth

Almirall H1 2025 Results

PR Newswire associated0

Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference